Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Genetic diseases stories

Nov 20, 2026

FDA rejects Capricor's Duchenne muscular dystrophy cell therapy for second time

The FDA declined to approve Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy, citing significant issues with trial data reliability. This is the second rejection for the treatment, dealing a major blow to the company.

Nov 20, 2026·4 sources
00
Nov 19, 2026

Sanofi wins first FDA approval for neurological symptoms of Gaucher disease

The FDA approved Sanofi's Infilbray, a brain-penetrating small molecule that is the first therapy cleared in the US to treat the neurological symptoms of Gaucher disease type 3.

Nov 19, 2026·3 sources
00
Nov 10, 2026

Beam Therapeutics base-editing sickle cell therapy succeeds in pivotal trial

Beam Therapeutics announced its base-edited sickle cell therapy met its primary endpoint in a Phase 1/2 clinical trial, potentially positioning it as a third one-time curative therapy for the disease.

Nov 10, 2026·2 sources
00
Nov 6, 2026

Novartis links two tumor cases in children to Zolgensma gene therapy

Novartis disclosed that two of nine reported tumor cases in Zolgensma recipients showed evidence of the viral delivery vector integrating into patient DNA, raising new safety questions for the gene therapy field.

Nov 6, 2026·3 sources
00

FDA launches investigation into Novartis' Zolgensma over cancer cases

The FDA is investigating a 'serious risk' of cancer linked to Novartis' spinal muscular atrophy gene therapy Zolgensma, following reports of tumor cases in children. This follows Novartis linking two tumor cases in children to the therapy.

Nov 6, 2026·2 sources
00

Sarepta halts enrollment in confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.

Nov 6, 2026·2 sources
00
Nov 5, 2026

Novartis reports nine tumor cases possibly linked to Zolgensma gene therapy

Novartis confirmed that nine patients who received its spinal muscular atrophy gene therapy Zolgensma have developed tumors following treatment, with seven cases newly reported, raising serious safety concerns about the widely used pediatric drug.

Nov 5, 2026·3 sources
00
Nov 3, 2026

Ultragenyx to cut 20% of workforce after Wilson disease gene therapy failure

Ultragenyx Therapeutics announced plans to lay off approximately 20% of its employees and discontinue development of its Wilson disease gene therapy GTX-102 following a major setback in Angelman syndrome trials.

Nov 3, 2026·2 sources
00

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Servier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.

Nov 3, 2026·2 sources
00
Nov 2, 2026

FDA sets May 2027 review date for uniQure's Huntington's gene therapy

The FDA will review uniQure's gene therapy for Huntington's disease, with a decision expected in May 2027. The agency has also scheduled an advisory committee meeting.

Nov 2, 2026·2 sources
00
Oct 3, 2026

Z-basivarsen shows sustained benefits in myotonic dystrophy type 1 trial

An investigational drug, z-basivarsen, demonstrated sustained improvements in myotonia, motor function, and strength in patients with myotonic dystrophy type 1, according to analysis from the ACHIEVE trial. The findings suggest potential therapeutic benefits for this genetic neuromuscular disorder.

Oct 3, 2026·2 sources
00

Top claims

  • ▪A group of 28 physicians and researchers involved in deramiocel development sent a letter to senior FDA leadership in October 2026 advocating for the drug's approval
  • ▪Capricor's original deramiocel approval application was denied in July 2025 after the FDA found it lacked substantial evidence of effectiveness
  • ▪Deramiocel was designed to protect muscle tissue that Duchenne muscular dystrophy progressively destroys, distinguishing it from other approved drugs that slow the condition or address its genetic mutations

Subtopics

Gene therapy7Clinical trials6Pharmaceutical Industry6Drug Policy, Pricing & Approval5Drug safety4Rare diseases4Cancer & Oncology3FDA drug approval3Post-market surveillance3Accelerated approval pathways2Clinical trial design2Corporate layoffs2Drug development2Angelman syndrome1Biotech innovation1Child health1Clinical trial endpoints1Clinical trial transparency1Corporate restructuring1Eli Lilly1Facebook1FDA regulation1FDA regulatory approval1Gene editing1

Related timelines

Congress

110 stories

Trump administration

161 stories

Crypto hacks

100 stories

Russia-Ukraine war

136 stories

US midterm elections

102 stories